[go: up one dir, main page]

WO2004012653A3 - Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes - Google Patents

Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes Download PDF

Info

Publication number
WO2004012653A3
WO2004012653A3 PCT/US2003/018944 US0318944W WO2004012653A3 WO 2004012653 A3 WO2004012653 A3 WO 2004012653A3 US 0318944 W US0318944 W US 0318944W WO 2004012653 A3 WO2004012653 A3 WO 2004012653A3
Authority
WO
WIPO (PCT)
Prior art keywords
dehydroepiandrosterone
pulmonary disease
chronic obstructive
obstructive pulmonary
compostions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/018944
Other languages
English (en)
Other versions
WO2004012653A2 (fr
Inventor
Sherry A Leonard
Keith A Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenesis Pharmaceuticals Inc
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Priority to AU2003276836A priority Critical patent/AU2003276836B2/en
Priority to BR0311883-5A priority patent/BR0311883A/pt
Priority to EP03766816A priority patent/EP1513509A4/fr
Priority to MXPA04012720A priority patent/MXPA04012720A/es
Priority to JP2004525996A priority patent/JP2005537296A/ja
Priority to CA002489124A priority patent/CA2489124A1/fr
Publication of WO2004012653A2 publication Critical patent/WO2004012653A2/fr
Publication of WO2004012653A3 publication Critical patent/WO2004012653A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne un contenant hermétique qui contient une formulation de poudre comprenant une déhydroépiandrostérone, un ou des analogue(s) ou sel(s) de celle-ci, ou un excipient pharmaceutique ou vétérinaire ou un diluant, et qui présente une taille de particules comprise entre environ 0,1 νm et environ 100 νm. La formulation peut servir à traiter ou à prévenir l'asthme, la bronchopneumopathie obstructive chronique, l'inflammation pulmonaire et d'autres maladies ou affections respiratoires. Cette formulation peut être préparée par broyage au jet et s'administre par les voies respiratoires ou par d'autres voies au moyen d'un nébuliseur. Le contenant hermétique est fourni dans un dispositif et/ou une trousse thérapeutique.
PCT/US2003/018944 2002-06-17 2003-06-17 Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes Ceased WO2004012653A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003276836A AU2003276836B2 (en) 2002-06-17 2003-06-17 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
BR0311883-5A BR0311883A (pt) 2002-06-17 2003-06-17 Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente
EP03766816A EP1513509A4 (fr) 2002-06-17 2003-06-17 Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes
MXPA04012720A MXPA04012720A (es) 2002-06-17 2003-06-17 Formulaciones de deshidroepiandrosterona para nebulizador y metodos para tratar asma o enfermedad pulmonar obstructiva cronica utilizando composiciones de la misma.
JP2004525996A JP2005537296A (ja) 2002-06-17 2003-06-17 デヒドロエピアンドロステロンの噴霧器製剤及びその組成物を使用することでの喘息又は慢性閉塞性肺疾患を治療するための方法
CA002489124A CA2489124A1 (fr) 2002-06-17 2003-06-17 Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38924202P 2002-06-17 2002-06-17
US60/389,242 2002-06-17
US47798703P 2003-06-11 2003-06-11
US60/477,987 2003-06-11

Publications (2)

Publication Number Publication Date
WO2004012653A2 WO2004012653A2 (fr) 2004-02-12
WO2004012653A3 true WO2004012653A3 (fr) 2004-07-08

Family

ID=29740120

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/018945 Ceased WO2003105775A2 (fr) 2002-06-17 2003-06-17 Dihydrate dehydroepiandrosterone et methodes de traitement de l'asthme ou de la broncho-pneumopathie obstructive chronique a l'aide de compositions associees
PCT/US2003/018944 Ceased WO2004012653A2 (fr) 2002-06-17 2003-06-17 Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018945 Ceased WO2003105775A2 (fr) 2002-06-17 2003-06-17 Dihydrate dehydroepiandrosterone et methodes de traitement de l'asthme ou de la broncho-pneumopathie obstructive chronique a l'aide de compositions associees

Country Status (11)

Country Link
US (1) US20090087389A1 (fr)
EP (2) EP1553954A4 (fr)
JP (2) JP2005530820A (fr)
KR (2) KR20060011784A (fr)
CN (2) CN100540007C (fr)
AU (2) AU2003276836B2 (fr)
BR (2) BR0311885A (fr)
CA (2) CA2491846A1 (fr)
IL (2) IL165291A0 (fr)
MX (2) MXPA04012728A (fr)
WO (2) WO2003105775A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506445A (ja) * 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
WO2006134022A1 (fr) * 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Inhibiteurs mrp iv pour le traitement de maladies respiratoires
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
WO2007117661A2 (fr) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd, Microparticules médicamenteuses
WO2008151235A2 (fr) * 2007-06-05 2008-12-11 Forma Therapeutics, Inc. Procédés et compositions pour administrer des médicaments aux poumons
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
AU2009308181B2 (en) 2008-10-24 2015-12-03 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
CA2744940A1 (fr) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Procedes et compositions pour la delivrance de medicaments aux poumons
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
SI2571506T1 (sl) 2010-05-20 2017-12-29 Cempra Pharmaceuticals, Inc. Postopki za pripravo makrolidov in ketolidov ter njihovih intermediatov
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
CN105163785A (zh) * 2013-03-14 2015-12-16 森普拉制药公司 用于治疗呼吸道疾病的方法及其制剂
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
US10130713B2 (en) * 2013-04-19 2018-11-20 The Methodist Hospital Cocrystalline DHEA formulations
WO2025076250A1 (fr) * 2023-10-04 2025-04-10 The Trustees Of Indiana University Compositions à libération lente et méthodes d'obstruction inflammatoire des voies respiratoires

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379842A (en) * 1980-02-13 1983-04-12 Hoffmann-La Roche Inc. Process for the manufacture of 1α-hydroxydehydroepiandrosterone
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4789669A (en) * 1986-10-20 1988-12-06 Kanebo, Ltd. Vaginal suppository
US5861391A (en) * 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943987A (en) * 1974-10-17 1976-03-16 Rossi Thomas J Reclosable air-tight containers with evacuation means
US4393066A (en) * 1981-06-05 1983-07-12 Garrett David M Method for treatment of herpetic lesions
US4499064A (en) * 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
CH673459A5 (fr) * 1987-05-15 1990-03-15 Eprova Ag
EP0326034B1 (fr) * 1988-01-28 1992-08-26 Peter Dr. Költringer Preparation combinée pour le traitement des maladies et desordres des cellules et des fibres nerveuses
FR2631828B1 (fr) * 1988-05-27 1994-05-20 Spiral Recherche Developpement Utilisation d'une substance folinique en tant qu'agent antiagregant plaquettaire
US4931441A (en) * 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
IT1229517B (it) * 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
NL8901432A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Bij koelkasttemperatuur stabiele waterige folinaatoplossing, alsmede werkwijze ter bereiding daarvan.
US4985443A (en) * 1989-08-04 1991-01-15 Montes Leopoldo F Method and composition for treating vitiligo
US5173488A (en) * 1989-08-21 1992-12-22 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US5266312A (en) * 1992-01-07 1993-11-30 National Jewis Center For Immunology And Respiratory Medicine Method for treating a steroid resistant condition via administration of gamma interferon
DE69328771T2 (de) * 1992-02-24 2000-12-07 East Carolina University, Greenville Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
DE69433994T2 (de) * 1993-01-19 2005-09-22 Endorecherche Inc., Ste-Foy Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
SK103195A3 (en) * 1993-03-09 1996-12-04 Univ Utah Res Found Use of dehydroepiandrosterone derivative for pharmaceutical compositions production and pharmaceutical composition containing dehydroepiandrosterone derivative
US5635496A (en) * 1993-03-09 1997-06-03 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5811418A (en) * 1993-03-09 1998-09-22 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
JPH10509976A (ja) * 1994-11-30 1998-09-29 アムール リサーチ コーポレーション ホスホコリン薬物誘導体
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
US5767278A (en) * 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
DE69731302T3 (de) * 1996-07-22 2011-01-20 Renovo Ltd. Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2260584C (fr) * 1998-02-04 2007-07-31 Charlotte-Mecklenburg Hospital D/B/A Carolinas Medical Center Derives de l'androsterone pour inhiber la fixation par l'adn de l'ap-1 et la proliferation de muscle lisse dans les voies aeriennes
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2347856C (fr) * 1998-11-13 2009-02-17 Jago Research Ag Poudre seche pour inhalation
MXPA00011329A (es) * 1999-03-18 2002-04-17 Genelabs Tech Inc Composicion de dhea y metodo.
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379842A (en) * 1980-02-13 1983-04-12 Hoffmann-La Roche Inc. Process for the manufacture of 1α-hydroxydehydroepiandrosterone
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4789669A (en) * 1986-10-20 1988-12-06 Kanebo, Ltd. Vaginal suppository
US5861391A (en) * 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)

Also Published As

Publication number Publication date
WO2003105775A3 (fr) 2004-04-08
MXPA04012728A (es) 2006-02-02
BR0311883A (pt) 2005-04-05
US20090087389A1 (en) 2009-04-02
AU2003276836A1 (en) 2004-02-23
EP1513509A2 (fr) 2005-03-16
KR101005819B1 (ko) 2011-01-05
IL165378A0 (en) 2006-01-15
WO2004012653A2 (fr) 2004-02-12
JP2005537296A (ja) 2005-12-08
AU2003276836B2 (en) 2007-05-10
CN1658884A (zh) 2005-08-24
KR20050037515A (ko) 2005-04-22
CN1681520A (zh) 2005-10-12
BR0311885A (pt) 2005-04-05
KR20060011784A (ko) 2006-02-03
CA2491846A1 (fr) 2003-12-24
AU2003269889A1 (en) 2003-12-31
EP1553954A4 (fr) 2009-12-23
WO2003105775A2 (fr) 2003-12-24
AU2003269889B2 (en) 2007-04-19
IL165291A0 (en) 2005-12-18
CA2489124A1 (fr) 2004-12-02
MXPA04012720A (es) 2007-03-23
JP2005530820A (ja) 2005-10-13
EP1553954A2 (fr) 2005-07-20
CN100540007C (zh) 2009-09-16
EP1513509A4 (fr) 2009-05-27

Similar Documents

Publication Publication Date Title
WO2004012653A3 (fr) Formulations de dehydroepiandrosterone a nebuliser et methodes de traitement de l'asthme ou de la bronchopneumopathie obstructive chronique a l'aide des compositions correspondantes
CA2395653A1 (fr) Nouvelle poudre a inhaler a teneur en tiotropium
EP2201964A3 (fr) Formulation de surfin de formotérol
ATE347361T1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
CA2474479A1 (fr) Composition pour inhalation
AU2001258343A1 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
WO2001039745A3 (fr) Utilisation de composes organiques dans le traitement d'une maladie
PL312210A1 (en) Inhalable compositions
CA2412561A1 (fr) Distribution hautement efficace d'une grande quantite d'aerosol therapeutique
CA2195065A1 (fr) Composition pour inhalation
WO2005025506A3 (fr) Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
CA2550841A1 (fr) Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
CA2478980A1 (fr) Apport pulmonaire de levodopa
NZ541745A (en) (spiro[8-azaniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-4[hydroxydiphenylacetyl)oxy]chloride (1a, 3b, 5a)) containing compositions
EP1124544B1 (fr) Formulation pharmaceutique sous forme de poudre seche
TW200602054A (en) Use of compounds in a dry powder inhaler
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
WO2004017942A8 (fr) Compositions pour inhalation contenant une proportion elevee de medicament
JPH05123398A (ja) 咽喉保護吸入剤並びに吸入器具
WO2004047796A3 (fr) Formulation pulverulente pour inhalation contenant du tiotropium
WO2005011616A3 (fr) Association de dehydroepiandrosterone ou de sulfate de dehydroepiandrosterone et de cromone dans le traitement de l'asthme ou de la maladie pulmonaire obstructive chronique
WO2002062317A3 (fr) Medicaments
WO2007046113A3 (fr) Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede
JP2004523536A5 (fr)
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 3700/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003276836

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003766816

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2489124

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20038136813

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012720

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004525996

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047020590

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003766816

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047020590

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2003276836

Country of ref document: AU